De Cian W, Sassella D, Wynne B A
Pharmacia SpA, Milan, Italy.
Scand J Infect Dis Suppl. 1995;98:22-6.
Effective new therapies are required to combat the increasing incidence of mycobacterial infections. Rifabutin has been investigated in studies conducted in various countries around the world, and in the treatment of tuberculosis rifabutin in combination regimen has been shown to be as effective as rifampicin. Rifabutin is active in approximately 30% of patients with tuberculosis resistant to standard therapies, including rifampicin and/or isoniazid. Placebo-controlled studies of rifabutin in the treatment of Mycobacterium avium-intracellulare complex (MAC) infection in AIDS patients have provided evidence for the inclusion of rifabutin in multidrug regimens. Rifabutin as a single agent is the only drug approved for the prophylaxis of MAC infection. Clinical experience indicates that rifabutin is well tolerated and that it does not reduce the tolerability of combination regimens.
需要有效的新疗法来应对分枝杆菌感染发病率的不断上升。利福布汀已在世界各国进行的研究中得到调查，在结核病治疗中，利福布汀联合用药方案已被证明与利福平一样有效。利福布汀对约30%对包括利福平和/或异烟肼在内的标准疗法耐药的结核病患者有活性。在艾滋病患者中进行的利福布汀治疗鸟分枝杆菌复合群（MAC）感染的安慰剂对照研究为将利福布汀纳入多药方案提供了证据。利福布汀作为单一药物是唯一被批准用于预防MAC感染的药物。临床经验表明，利福布汀耐受性良好，并且不会降低联合用药方案的耐受性。
